Nutramax Cosamin®DS Joint Health Supplement Description
The ONLY glucosamine/chondroitin sulfate used in controlled clinical studies conducted and published in the U.S.
#1 Doctor and Pharmacist Recommended Brand Cosamin®DS is superior to other joint health supplements.† And now, available in NEW Easy-To-Swallow Scored Tablets.
Only CosaminDS contains researched 95% pure low molecular weight chondroitin sulfate (CS) and 99% pure glucosamine HCl. This exclusive combination has been shown to be more effective than either of the two ingredients alone!
The difference in CosaminDS is its low molecular weight CS, which is the approved CS used in European studies and has been shown to help safely manage joint discomfort.
Only CosaminDS contains the high purity, low molecular weight chondroitin sulfate selected by the National Institutes of Health (NIH) for a major clinical study.
Only CosaminDS contains the researched high purity weight chondroitin sulfate allowing you to maintain your comfort level at a lower intake of tablets.
†Sources: Surveys conducted by Orthopedics Today of orthopedic surgeons and rheumatologists in April, 2000 and November, 2001 relating to glucosamine/chondroitin brands. CosaminDS is the #1 glucosamine/chondroitin brand of the Pharmacy Times® OTC Products 2001 Survey of Pharmacists Recommendations.
Suggested Daily Intake: take 1-2 tablets daily.
Initial 1 to 2 months: Take 3 tablets daily (may be taken once or throughout the day).
For children, consult your physician or pharmacist.
Yeast, corn, wheat, sugar, soy, milk, preservatives, artificial colors and flavors.
These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Nutramax Cosamin®DS Joint Health Supplement -- 75 Tablets
try with caution
I can not say this was that effective for my condition. Maybe I should have used it longer. I can not say I got great relief. I used this in place of a product the doctor gave to me, it worked as well. I would recommend it to others with caution.
December 9, 2011